Dipulimab (Dupixent ®) is a new type of treatment - so-called biological treatment - for atopic eczema.
It inhibits communication between immune cells in the body. The injections are given every 14 days, and the effect comes within 16 weeks, but usually within a week.
Atopic eczema is a disease that causes red, dry and itchy skin.
Many children have atopic eczema in a mild form, but in some older children and adults the disease can be almost disabling.
The cause of the disease is not known, but there is an interaction between heredity and environment that leads to weakened skin and an active immune system.
Allergy rarely plays a major role, but the disease occurs more frequently in people with pollen allergies and asthma. You can read more about atopic eczema here . [UPDATE LINK]
Dupixent is considered a safe treatment, and in addition to the discomfort with the injection, in quite a few people Dupixent can cause side effects such as itching and discomfort from the eyes.
Sometimes eye problems can be so severe that you have to make an appointment with an ophthalmologist.
There are currently strict requirements for who can be offered this treatment.
A dermatologist must apply to the hospital for approval before starting Dupixent.
The patient must have a long-term eczema disease that results in a significantly reduced quality of life.
In addition, other treatment such as moisturisers, cortisone creams and tablet treatment (for example Sandiummun) against atopic eczema must be tried.
About 2/3 of the patients who try Dupixent achieve a good effect from the treatment.
